{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ARRY-142886%2C+MEK+inhibitor%3B+oral", "query": { "intervention": "ARRY-142886, MEK inhibitor; oral" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 16, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ARRY-142886%2C+MEK+inhibitor%3B+oral&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-10T03:01:41.920Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00866177", "title": "MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage III Skin Melanoma", "Stage IV Skin Melanoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Selumetinib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 167, "start_date": "2009-03", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2015-08-11", "last_synced_at": "2026-10-10T03:01:41.920Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00866177" }, { "nct_id": "NCT03326310", "title": "Selumetinib and Azacitidine in High Risk Chronic Blood Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloid Leukemia", "Myelofibroses" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Selumetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2018-09-04", "completion_date": "2027-09-04", "has_results": false, "last_update_posted_date": "2025-12-29", "last_synced_at": "2026-10-10T03:01:41.920Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03326310" }, { "nct_id": "NCT00085787", "title": "A Study of ARRY-142886 in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "ARRY-142886, MEK inhibitor; oral", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Array Biopharma, now a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2004-06", "completion_date": "2007-02", "has_results": false, "last_update_posted_date": "2020-10-14", "last_synced_at": "2026-10-10T03:01:41.920Z", "location_count": 3, "location_summary": "Aurora, Colorado • Rochester, Minnesota • Philadelphia, Pennsylvania", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00085787" }, { "nct_id": "NCT01085214", "title": "AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Selumetinib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2010-03", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2015-08-19", "last_synced_at": "2026-10-10T03:01:41.920Z", "location_count": 9, "location_summary": "Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 5 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01085214" }, { "nct_id": "NCT01362803", "title": "AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neurofibromatosis 1", "Neurofibromatosis Type 1", "NF1", "Neurofibroma, Plexiform" ], "interventions": [ { "name": "AZD6244", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Years to 18 Years" }, "enrollment_count": 99, "start_date": "2011-09-21", "completion_date": "2032-01-01", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-10T03:01:41.920Z", "location_count": 4, "location_summary": "Washington D.C., District of Columbia • Bethesda, Maryland • Cincinnati, Ohio + 1 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01362803" }, { "nct_id": "NCT03801369", "title": "AMTEC IIT: Phase 2 Multiarm Study in TNBC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Selumetinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Gordon Mills, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2018-12-12", "completion_date": "2024-12-23", "has_results": true, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-10-10T03:01:41.920Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03801369" }, { "nct_id": "NCT01166126", "title": "Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mucosal Melanoma", "Recurrent Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "temsirolimus", "type": "DRUG" }, { "name": "selumetinib", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2010-10", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2014-05-15", "last_synced_at": "2026-10-10T03:01:41.920Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01166126" }, { "nct_id": "NCT01750281", "title": "Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV" ], "interventions": [ { "name": "Selumetinib 75 mg", "type": "DRUG" }, { "name": "Docetaxel 75 mg/m2", "type": "DRUG" }, { "name": "Docetaxel 60 mg/m2", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 212, "start_date": "2012-12-18", "completion_date": "2022-10-31", "has_results": true, "last_update_posted_date": "2023-10-24", "last_synced_at": "2026-10-10T03:01:41.920Z", "location_count": 13, "location_summary": "Santa Monica, California • Aurora, Colorado • Hollywood, Florida + 9 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01750281" }, { "nct_id": "NCT01217450", "title": "Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "selumetinib", "type": "DRUG" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2012-10", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2014-05-29", "last_synced_at": "2026-10-10T03:01:41.920Z", "location_count": 3, "location_summary": "Bethesda, Maryland • Madison, Wisconsin • Milwaukee, Wisconsin", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Madison", "state": "Wisconsin" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01217450" }, { "nct_id": "NCT01933932", "title": "Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV" ], "interventions": [ { "name": "Selumetinib", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Pegylated G-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 510, "start_date": "2013-09-25", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-10T03:01:41.920Z", "location_count": 17, "location_summary": "Aurora, Colorado • Pembroke Pines, Florida • Atlanta, Georgia + 11 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Metairie", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01933932" } ] }